journal article·2022-09-28Open access

Smoking and High-Sensitivity Troponin I Levels in Young and Healthy Adults from the General Population

Kirsten Grossmann, Stefanie Aeschbacher, Niklas Wohlwend, Steffen Blum, Ornella C. Weideli, Julia Telser, Martin Risch, Lorenz Risch, David Conen

Applied Sciences· Volume 12· Issue 19

Abstract

Lower troponin concentrations measured in smokers in a healthy population raise the question of whether a lower troponin threshold should be considered for tobacco users. We aim to evaluate differences in troponin levels according to the smoking status in healthy young adults. Participants aged 25–41 years were enrolled in a population-based observational study. The smoking status was self-assessed, and participants were classified as never-, past-, and current smokers. Pack-years of smoking were calculated. High-sensitivity cardiac troponin I (hs-cTnI) concentrations were measured from thawed blood samples, and associations were assessed using multivariable linear regression analyses. We included 2155 subjects in this analysis. The mean (SD) age was 35.4 ± 5.22 years; 53% were women. The median hs-cTnI levels across smoking status categories were 0.70 (interquartile range 0.43–1.23) ng/L in never smokers (n = 1174), 0.69 (interquartile range 0.43–1.28) ng/L in past smokers (n = 503), and 0.67 (interquartile range 0.41–1.04) ng/L in current smokers (n = 478), p = 0.04. The troponin levels remained significantly lower in current smokers after adjustment for potential confounders (β-coefficient [95%CI] of −0.08 [−0.25; −0.08], p < 0.001). Our results confirm that current smokers have lower hs-cTnI levels than past or never smokers, with a significant dose–response relationship among current smokers. The absolute differences in hs-cTnI levels were small.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Acute Myocardial Infarction Research · Smoking Behavior and Cessation · Cardiovascular Effects of Exercise

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Dr Risch Medical Laboratory, 9490 Vaduz, Liechtenstein

Faculty of Medical Sciences, Private University Liechtenstein, 9495 Triesen, Liechtenstein

Cardiovascular Research Institute Basel and Division of Cardiology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland

Population Health Research Institute, McMaster University, Hamilton, ON L8L 2X2, Canada

Dr Risch Medical Laboratory, 9470 Buchs, Switzerland

Division of Laboratory Medicine, Cantonal Hospital Graubünden, 7007 Chur, Switzerland

Department of Laboratory Medicine, Institute of Clinical Chemistry, Inselspital Bern University Hospital, University of Berne, 3012 Berne, Switzerland

Funding

the Liechtenstein Government · the Swiss National Science Foundation · the Swiss Heart Foundation · the Swiss Society of Hypertension · the University of Basel · the University Hospital Basel · the Hanela Foundation, Schiller AG, and Novartis

References (21)

Show source-provided references
1. Troponin I and cardiovascular risk prediction in the general population: The BiomarCaRE consortium10.1093/eurheartj/ehw172 ↗
2. Prognostic value of basal high-sensitive cardiac troponin levels on mortality in the general population10.1097/MD.0000000000005703 ↗
3. Cardiac Troponin T and Troponin I in the General Population10.1161/CIRCULATIONAHA.118.038529 ↗
4. Current Smoking Is Associated With Lower Concentrations of High-Sensitivity Cardiac Troponin T in Patients With Stable Coronary Artery Disease: The PEACE Trial10.1161/CIRCULATIONAHA.119.041991 ↗
5. Influence of cigarette smoking on cardiac biomarkers: The Atherosclerosis Risk in Communities (ARIC) Study10.1002/ejhf.511 ↗
6. Impact of Smoking on Circulating Cardiac Troponin I Concentrations and Cardiovascular Events in the General Population10.1161/CIRCULATIONAHA.116.023726 ↗
7. Tobacco Consumption and High-Sensitivity Cardiac Troponin I in the General Population: The HUNT Study10.1161/JAHA.121.021776 ↗
8. Smoking intensity (pack/day) is a better measure than pack-years or smoking status for modeling cardiovascular disease outcomes10.1016/j.jclinepi.2016.09.010 ↗
9. Genetic and phenotypic determinants of blood pressure and other cardiovascular risk factors (GAPP)
10. Factors independently associated with cardiac troponin I levels in young and healthy adults from the general population10.1007/s00392-016-1026-5 ↗
11. Nicotine addiction and its assessment
12. The Fagerström test for nicotine dependence: A comparison of standard scoring and latent class analysis approaches10.1016/j.drugalcdep.2004.04.021 ↗
13. The Fagerström Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire10.1111/j.1360-0443.1991.tb01879.x ↗
14. Relationship Between High-Sensitivity Cardiac Troponin I and Blood Pressure Among Young and Healthy Adults10.1093/ajh/hpu226 ↗
15. Ultrasensitive flow-based immunoassays using singlemolecule counting10.1373/clinchem.2007.091181 ↗
16. International Physical Activity Questionnaire: 12-Country Reliability and Validity10.1249/01.MSS.0000078924.61453.FB ↗
17. IBM Corp (Released IBM SPSS Statistics for Windows, 2019). Released IBM SPSS Statistics for Windows, Version 26.
18. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study10.1016/S0140-6736(10)60834-3 ↗
19. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary10.1016/j.jacc.2019.03.009 ↗
20. Neumann, J., Havulinna, A.S., Zeller, T., Appelbaum, S., Kunnas, T., Nikkari, S., Jousilahti, P., Blankenberg, S., Sydow, K., and Salomaa, V. (2014). Comparison of Three Troponins as Predictors of Future Cardiovascular Events—Prospective Results from the FINRISK and BiomaCaRE Studies. PLoS ONE, 9.10.1371/journal.pone.0090063 ↗
21. Is twice better than once?—Challenges of troponin measurements for risk prediction in the general population10.21037/atm.2019.08.03 ↗